Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study

Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843–55.

CAS  Article  Google Scholar 

Ponticelli C, Podesta MA, Moroni G. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease. Kidney Int. 2020;98(5):1149–59.

CAS  Article  Google Scholar 

Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009–10. PLoS ONE. 2012;7(11): e50046.

CAS  Article  Google Scholar 

Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–5.

CAS  Article  Google Scholar 

Dalbeth N, House ME, Horne A, Taylor WJ. Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskelet Disord. 2013;14:363.

Article  Google Scholar 

Chinese consensus expert group on the diagnosis and treatment of chronic kidney disease patients with hyperuricemia. Chinese experts consensus on the management of chronic kidney disease with hyperuricemia Chin J Nephrol. 2017;33(6):463–9.

Neogi T, Jansen TLTA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumatol. 2015;67(10):2557–68.

Article  Google Scholar 

Novella-Navarro M, Cabrera-Alarcon JL, Diaz-Torne C, Aramburu-Munoz F, Janta I, de la Ortega OM, et al. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3. Rheumatol Int. 2020;40(7):1081–7.

CAS  Article  Google Scholar 

Juge PA, Truchetet ME, Pillebout E, Ottaviani S, Vigneau C, Loustau C, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: a retrospective study of 10 centers. Joint Bone Spine. 2017;84(5):595–8.

CAS  Article  Google Scholar 

Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol. 2016;68(8):2035–43.

CAS  Article  Google Scholar 

Chung TT, Yu KH, Kuo CF, Luo SF, Chiou MJ, Lan WC, et al. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients. Arthritis Res Ther. 2019;21(1):210.

Article  Google Scholar 

Lee TH, Chen JJ, Wu CY, Yang CW, Yang HY. Hyperuricemia and progression of chronic kidney disease: a review from physiology and pathogenesis to the role of urate-lowering therapy. Diagnostics (Basel, Switzerland). 2021;11(9):1674.

CAS  PubMed Central  Google Scholar 

Lin TC, Hung LY, Chen YC, Lo WC, Lin CH, Tam KW, et al. Effects of febuxostat on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Medicine. 2019;98(29):e16311.

CAS  Article  Google Scholar 

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.

CAS  Article  Google Scholar 

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744–60.

Article  Google Scholar 

Liang N, Sun MS, Sun RX, Xu T, Cui LL, Wang C, et al. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Ther. 2019;21(1).

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150.

Google Scholar 

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–70.

CAS  Article  Google Scholar 

Levey AGT, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:A155.

Google Scholar 

Chinese Rheumatology Association. 2016 Guidelines for the diagnosis and treatment of gout in China. Zhong Hua Nei Ke Za Zhi. 2016;55(11):892–9.

Google Scholar 

Kamel B, Graham GG, Williams KM, Pile KD, Day RO. Clinical pharmacokinetics and pharmacodynamics of febuxostat. Clin Pharmacokinet. 2017;56(5):459–75.

CAS  Article  Google Scholar 

Stamp LK, Farquhar H, Pisaniello HL, Vargas-Santos AB, Fisher M, Mount DB, et al. Management of gout in chronic kidney disease: a G-CAN consensus statement on the research priorities. Nat Rev Rheumatol. 2021;17(10):633–41.

Article  Google Scholar 

Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239–47.

CAS  Article  Google Scholar 

Li L, Yang C, Zhao YL, Zeng XX, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. Bmc Nephrol. 2014;15.

Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–13.

CAS  Article  Google Scholar 

Alshahawey M, Shahin SM, Elsaid TW, Sabri NA. Effect of febuxostat on the endothelial dysfunction in hemodialysis patients: a randomized, placebo-controlled double-blinded study. Am J Nephrol. 2017;45(5):452–9.

CAS  Article  Google Scholar 

Mukri MNA, Kong WY, Mustafar R, Shaharir SS, Shah SA, Abdul Gafor AH, et al. Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: a 6-months open-label, randomized controlled trial. EXCLI J. 2018;17:563–75.

PubMed  PubMed Central  Google Scholar 

Tsuda H, Kawada N, Kaimori JY, Kitamura H, Moriyama T, Rakugi H, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427(2):266–72.

CAS  Article  Google Scholar 

Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16(4):549–56.

CAS  Article  Google Scholar 

Kim SH, Lee SY, Kim JM, Son CN. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis. Korean J Intern Med. 2020;35(4):998–1003.

CAS  Article  Google Scholar 

Novella-Navarro M, Cabrera-Alarcon JL, Diaz-Torne C, Aramburu-Munoz F, Janta I, de la Maria CO, et al. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3. Rheumatol Int. 2020;40(7):1081–7.

CAS  Article  Google Scholar 

Sharma G, Dubey A, Nolkha N, Singh JA. Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211016661.

Article  Google Scholar 

Xu SY, Liu XY, Ming J, Chen SR, Wang YG, Liu XM, et al. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. Int J Rheum Dis. 2015;18(6):669–78.

Article  Google Scholar 

Zhang FC, Liu ZC, Jiang LD, Zhang H, Zhao DB, Li Y, et al. A randomized, double-blind, non-inferiority study of febuxostat versus allopurinol in hyperuricemic Chinese subjects with or without gout. Rheumatol Ther. 2019;6(4):543–57.

Article  Google Scholar 

Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.

Article  Google Scholar 

Mu Z, Wang W, Wang J, Lv W, Chen Y, Wang F, et al. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial. Clin Rheumatol. 2019;38(12):3511–9.

Article  Google Scholar 

Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765–70.

Article  Google Scholar 

Tang YM, Zhang L, Zhu SZ, Pan JJ, Zhou SH, He TJ, et al. Gout in China, 1990–2017: the Global Burden of Disease Study 2017. Public Health. 2021;191:33–8.

CAS  Article  Google Scholar 

Pang S, Jiang Q, Sun P, Li Y, Zhu Y, Liu J, et al. Hyperuricemia prevalence and its association with metabolic disorders: a multicenter retrospective real-world study in China. Ann Transl Med. 2021;9(20):1550.

CAS  Article  Google Scholar 

Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69(7):1305–9.

Article  Google Scholar 

Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J. 1973;1(5851):449–51.

CAS  Article  Google Scholar 

Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65(10):1368–72.

CAS  Article  Google Scholar 

Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–49.

CAS  Article  Google Scholar 

留言 (0)

沒有登入
gif